The Wistar Institute 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   3 Trials   352 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-4800 / Inovio, The Wistar Institute
ChiCTR2000040146: A Phase II, Randomized, Double-blinded, Placebo-controlled, Dose-finding Clinical Study to Evaluate the Safety and Immunogenicity of Different Doses of INO-4800 Intradermal Injection Followed by Electroporation in Healthy Adult and Elderly Volunteers

Completed
2
640
 
pGX9501 1.0 mg / placebo ;pGX9501 1.0 mg / placebo ;pGX9501 2.0 mg/ placebo ;pGX9501 2.0 mg/ placebo
Jiangsu Provincial Center for Disease Control and Prevention; Advaccine (Suzhou) Biopharmaceutical, Ltd., Sponosor
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000038152: A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4800, Administered Intradermally Followed by Electroporation in Healthy Volunteers

Completed
1
45
 
Vaccine INO-4800 ;placebo
Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, Sponosor Investment
Novel Coronavirus Pneumonia (COVID-19)
 
 
VK-2019 / The Wistar Institute, Stanford University
NCT04925544: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Recruiting
2
61
US
VK-2019
Stanford University, National Institutes of Health (NIH), National Cancer Institute (NCI)
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
02/28
02/31
NCT06420349: NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, CCT 361814, CCT-361814, CCT361814, HSF1 Pathway Inhibitor NXP800, NXP-800, NXP800, VK2019, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Ultrasound-Guided Biopsy, Ultrasound Biopsy, Ultrasound Guided Biopsy
Mayo Clinic
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
05/26
05/26
NCT06789159: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Not yet recruiting
1
30
US
VK-2019
Thomas Jefferson University, National Cancer Institute (NCI), The Wistar Institute
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection
10/28
10/28
AZD5396 / Inovio, AstraZeneca
NCT05293249: dMAbs for Prevention of COVID-19

Active, not recruiting
1
61
US
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals
Healthy Volunteers
09/25
09/25
gamitrinib / Fox Chase Cancer Center, The Wistar Institute
NCT04827810: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Suspended
1
42
US
Gamitrinib
Fox Chase Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Lymphoma, Advanced Solid Tumor
06/26
12/26
AZD8076 / AstraZeneca, Inovio
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-4800 / Inovio, The Wistar Institute
ChiCTR2000040146: A Phase II, Randomized, Double-blinded, Placebo-controlled, Dose-finding Clinical Study to Evaluate the Safety and Immunogenicity of Different Doses of INO-4800 Intradermal Injection Followed by Electroporation in Healthy Adult and Elderly Volunteers

Completed
2
640
 
pGX9501 1.0 mg / placebo ;pGX9501 1.0 mg / placebo ;pGX9501 2.0 mg/ placebo ;pGX9501 2.0 mg/ placebo
Jiangsu Provincial Center for Disease Control and Prevention; Advaccine (Suzhou) Biopharmaceutical, Ltd., Sponosor
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000038152: A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4800, Administered Intradermally Followed by Electroporation in Healthy Volunteers

Completed
1
45
 
Vaccine INO-4800 ;placebo
Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, Sponosor Investment
Novel Coronavirus Pneumonia (COVID-19)
 
 
VK-2019 / The Wistar Institute, Stanford University
NCT04925544: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Recruiting
2
61
US
VK-2019
Stanford University, National Institutes of Health (NIH), National Cancer Institute (NCI)
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
02/28
02/31
NCT06420349: NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, CCT 361814, CCT-361814, CCT361814, HSF1 Pathway Inhibitor NXP800, NXP-800, NXP800, VK2019, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Ultrasound-Guided Biopsy, Ultrasound Biopsy, Ultrasound Guided Biopsy
Mayo Clinic
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
05/26
05/26
NCT06789159: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Not yet recruiting
1
30
US
VK-2019
Thomas Jefferson University, National Cancer Institute (NCI), The Wistar Institute
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection
10/28
10/28
AZD5396 / Inovio, AstraZeneca
NCT05293249: dMAbs for Prevention of COVID-19

Active, not recruiting
1
61
US
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals
Healthy Volunteers
09/25
09/25
gamitrinib / Fox Chase Cancer Center, The Wistar Institute
NCT04827810: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Suspended
1
42
US
Gamitrinib
Fox Chase Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Lymphoma, Advanced Solid Tumor
06/26
12/26
AZD8076 / AstraZeneca, Inovio
No trials found

Download Options